Effects of hormone replacement therapy on blood coagulation and fibrinolysis in hypertensive and normotensive postmenopausal women

Thrombosis Research

Volumn 115, Issue 5, 2005, Pages 359-366

  Sumino, Hiroyuki ^a   Ichikawa, Shuichi ^b   Sawada, Yoshie ^b   Sakamoto, Hironosuke ^a   Kumakura, Hisao ^b   Takayama, Yoshiaki ^b   Sakamaki, Tetsuo ^a   Kurabayashi, Masahiko ^a  

^a GUNMA UNIVERSITY   (Japan)

^b Cardiovasc Hosp of Central Japan   (Japan)

Author keywords

Coagulation; Estrogen; Fibrinolusis; Hypertension; Women

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; CONJUGATED ESTROGEN; D DIMER; FIBRINOGEN; MEDROXYPROGESTERONE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C;

ADULT; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYSIS; HEART RATE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 14144249453     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.08.017     Document Type: Article

References (37)

1. J. Stamler, J.D. Neaton, and D.N. Wentworth Blood pressure and risk of fatal coronary heart disease Hypertension 13 Suppl. I 1989 I-2 I-12
2. S. MacMahon, R. Peto, J. Cutler, R. Collins, P. Sorlie, and J. Neaton Blood pressure, stroke and coronary heart disease: II. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context Lancet 335 1990 827 838
3. V. Fuster, L. Badimon, J.J. Badimon, and J.H. Chesebro The pathogenesis of coronary artery disease and the acute coronary syndromes N. Engl. J. Med. 326 1992 242 250
4. K.A. Poli, G.H. Tofler, M.G. Larson, J.C. Evans, P.A. Sutherland, and I. Lipinska Association of blood pressure with fibrinolytic potential in the Framingham Offspring Population Circulation 101 2000 264 269
5. A.J. Lee The role of rheological and haemostatic factors in hypertension J. Hum. Hypertens. 11 1997 767 776
6. K. Landin, L. Tengborn, and U. Smith Elevated fibrinogen and plasminogen activator inhibitor in hypertension are related to metabolic risk factor for cardiovascular disease J. Intern. Med. 227 1990 273 278
7. U. Wall, C. Jern, A. Bergbrant, and S. Jern Enhanced levels of tissue-type plasminogen activator in borderline hypertension Hypertension 26 1995 796 800
8. B.M. Psaty, S.R. Heckbert, D. Atkins, D.S. Siscovick, T.D. Koepsell, and P.W. Wahl A review of the association of estrogens are progestins with cardiovascular disease in post-menopausal women Arch. Intern. Med. 153 1993 1421 1427
9. H. Jick, L.E. Derby, M.W. Myers, C. Vasilakis, and K.M. Newton Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens Lancet 348 1996 981 983
10. F. Grodstein, M.J. Stampfer, S.Z. Goldhaber, J.E. Manson, G.A. Colditz, and F.E. Speizer Prospective study of exogenous hormone and risk of pulmonary embolism in women Lancet 348 1996 983 987
11. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, and B. Riggs Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
12. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA 288 2002 321 333
13. R.A. Lobo, J.H. Pickar, R.A. Wild, B. Walsh, and E. Hirvonen Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women Obstet. Gynecol. 84 1994 987 995
14. K.K. Kon, R. Mincemoyer, M.N. Bui, G. Csako, F. Puncono, and V. Guetta Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women N. Engl. J. Med. 336 1997 683 690
15. Writing Group for the PEPI Trial Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial JAMA 273 1995 199 208
16. U-B. Kroon, G. Silfverstolpe, and L. Tengborn The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables Thromb. Haemost. 71 1994 420 423
17. T. Sporrong, L. Mattsson, G. Samsioe, L. Stigendal, and M. Hellgren Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women Br. J. Obstet. Gynaecol. 97 1990 939 944
18. M.W. van Baal, J.J. Emeis, M.J. Van der Mooren, H. Kessel, P. Kenemans, and C.D.A. Stehouwer Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomized placebo-controlled 12 week study Thromb. Haemost. 83 2000 29 34
19. M. Cushman, C. Legault, E. Barrett-Connor, M.L. Stefanick, C. Kessler, and H.L. Judd Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestine Interventions (PEPI) Study Circulation 100 1999 717 722
20. R.A. Lobo, T. Bush, B.R. Carr, and J.H. Pickar Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism Fertil. Steril. 76 2001 13 24
21. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure Arch. Intern. Med. 157 1997 2413 2446
22. R.D. Langdell, R.H. Wagner, and K.M. Brinkhous Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure J. Lab. Clin. Med. 41 1953 637 647
23. T.S. Karlsrud, L. Buo, A.O. Aasen, and H.T. Johansen Cleavage of plasma high molecular weight kininogen in surgical ICU patients Intensive Care Med. 22 1996 0 765
24. C.D. Richards, and J. Gauldie Role of cytokines in acute-phase response B.B. Aggarwal R.K. Puri Human Cytokines: Their Role in Disease and Therapy 1995 Blackwell Science Cambridge (MA) 253 269
25. W.B. Kannel, P.A. Wolf, W.P. Castelli, and D'R.B. Agostino Fibrinogen and risk of cardiovascular disease: the Framingham Study JAMA 258 1987 1183 1186
26. A. Haenni, and H. Lithell Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension Metabolism 45 1996 1221 1229
27. T. Lind, B. Sandhagen, A. Hagg, C. Morlin, and B.G. Danielson Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: results of a cross-over study J. Hum. Hypertens. 10 1996 199 205
28. I. Martinelli Risk factors in venous thromboembolism Thromb. Haemost. 86 2001 395 403
29. B. Zoller, and B. Dahlback Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis Lancet 343 1994 1536 1538
30. S. Fossum, N.O. Hoem, H. Gyonness, and K. Bjell Contact activation factors in plasma from women on estrogen replacement therapy after ovariohysterectomy Thromb. Res. 93 1999 161 170
31. B. Wiman Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease Thromb. Haemost. 74 1995 71 76
32. I. Juhan-Vague, and M.C. Alessi Plasminogen activator inhibitor 1 and atherothrombosis Thromb. Haemost. 70 1993 138 143
33. A.K. Haaland, O.H. Skjonsberg, A. Vaeret, R. Ruyter, and H.C. Godal A novel principle for assessment of stimulated fibrinolysis Thromb. Res. 62 1991 725 735
34. P.J. Declerck, P. Mombaerts, P. Holvoet, M. De Mol, and D. Collen Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis Thromb. Haemost. 58 1987 1024 1029
35. E.J. van Beek, B. van den Ende, R.J. Berckmans, Y.T. van der Heide, D.P. Brandjes, and A. Sturk A comparative analysis of D-dimer assays in patients with clinically suspected pulmonary embolism Thromb. Haemost. 70 1993 408 413
36. W.M. Feinberg, D.C. Bruck, M.E. Ring, and J.J. Corrigan Hemostatic markers in acute stroke Stroke 20 1989 592 597
37. C.W. Francis, D.G. Conaghan, W.I. Scott, and V.J. Marder Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction Circulation 75 1987 1170 1177